Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/2/2021
SIETES contiene 93212 citas

 
 
 1 a 11 de 11 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Yang M-S, Lee JY, Kim J, Kim G-W, Kim B-K, Kim Y, Park H-W, Cho S-H, Min K-U, Kang H-R. Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol 2020;8:febrero. [Ref.ID 103535]
2.Enlace a cita original Cita con resumen
Kim J, Farchione T, Potter A, Chen Q, Temple R. Esketamine for treatment-resistant depression — First FDA-approved antidepressant in a new class. N Engl J Med 2019;381:4 de julio. [Ref.ID 103124]
3.Enlace a cita original Cita con resumen
Kitchlu A, Shapiro J, Amir E, Garg AX, Kim J, Wald R, Harel Z. Representation of patients with chronic kidney disease in trials of cancer therapy. JAMA 2018;319:19 de junio. [Ref.ID 102790]
4.Enlace a cita original
Schoonen WM, Thomas SL, Somers EC, Smeeth L, Kim J, Evans S, Hall AJ. Do selected drugs increase the risk of lupus? A metched case-control study. Br J Clin Pharmacol 2010;70:588-96. [Ref.ID 89442]
5.Tiene citas relacionadas Cita con resumen
Chae YK, Kim J. Adverse outcomes associated with use of proton pump inhibitors and clopidogrel. JAMA 2009;302:20. [Ref.ID 86150]
6. Cita con resumen
Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E, and for the Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. The Cross Trial Safety analysis. Circulation 2008;117:2104-13. [Ref.ID 84245]
7.Tiene citas relacionadas Cita con resumen
Welton AJ, Vickers MR, Kim J, Ford D, Lawton BA, MacLennan AH, Meredith SK, Martín J, Meade TW, for the WISDOM team. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:550-3. [Ref.ID 84023]
8. Cita con resumen
Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujil K, Ishihara M, Saito Y, Tomoike H, Kitamura S, and the J-WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370:1483-93. [Ref.ID 81372]
9.Tiene citas relacionadas
Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff D A, Logothetis CJ. Bone-targetet therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001;357:336-41. [Ref.ID 55168]
10.
Abramson JS, Baker CJ, Fisher MC, Gerber MA, Meissner HC, Murray DL, Overturf GD, Prober C G, Rennels M B, Saari TN, Weiner LB, Whitley RJ, Pickering L K, Chilton L, Dowell SF, Embree J, Myers MG, Orenstein WA, Patriarca P A, Starke JR, Ledbetter EO, Kim J, Ward RM, Bates BA, Benitz WE, Burchfield DJ, Ring J C, Walls RP, Walson PD, Benett DR, Cvetkovich T, Hagino OR, MacLeod SM, Mithani S, Mulinare J, Riley L E, Yaffe SJ, Coté CJ, Meltzer EO, Campbell P, Jones J, Koteras RJ, American Academy of pediatrics, the Committe on Infectious Diseases and Committee on Drugs. Technical report: precautions regarding the use of aerosolized antibiotics. Pediatrics 2000;106:89-98. [Ref.ID 54585]
11.
Wang X, Moylan B, Leopold DA, Kim J, Rubenstein R C, Togias A, Proud D, Zeitlin PL, Cutting GR. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000;284:1814-9. [Ref.ID 53307]
Seleccionar todas
 
 1 a 11 de 11